Expect to See SGLT2 Inhibitors for Some Patients WithOUT Diabetes

You'll start to see more patients who DON'T have diabetes using SGLT2 inhibitors (Invokana, etc) for heart failure or kidney disease.

That's because evidence suggests these meds may improve outcomes when added to standard therapy.

For example, in some heart failure patients, adding Farxiga (dapagliflozin) or Jardiance (empagliflozin) may prevent hospitalization or cardiovascular (CV) death.

Get unlimited access through an Enterprise license

Hospital Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals